PT  - JOURNAL ARTICLE
AU  - Vicente Martínez
AU  - Jean Rivier
AU  - Lixin Wang
AU  - Yvette Taché
TI  - Central Injection of a New Corticotropin-Releasing Factor (CRF) Antagonist, Astressin, Blocks CRF- and Stress-Related Alterations of Gastric and Colonic Motor Function
DP  - 1997 Feb 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - 754--760
VI  - 280
IP  - 2
4099  - http://jpet.aspetjournals.org/content/280/2/754.short
4100  - http://jpet.aspetjournals.org/content/280/2/754.full
SO  - J Pharmacol Exp Ther1997 Feb 01; 280
AB  - The influence of central injection of a new corticotropin releasing factor (CRF) antagonist, astressin, {cyclo(30–33)[D-Phe12,Nle21,38,Glu30,Lys33]r/hCRF12–41)}, on exogenous and endogenous CRF-induced gastric ileus and stimulation of bowel discharges was investigated in conscious rats. Intracisternal (ic) CRF (0.6 μg) reduced gastric emptying of a noncaloric solution to 17.1 ± 4.9% compared with 50.1 ± 4.6% in control group injected ic with vehicle. Astressin (1, 3 and 10 μg, ic) dose dependently prevented ic CRF-induced delayed gastric emptying by 33, 100 and 100%, respectively, and had no effect on basal gastric emptying. Abdominal surgery with cecal manipulation (1 min) reduced gastric emptying to 19.8 ± 5.5% 3 hr postsurgery compared with 59.9 ± 5.2% after anesthesia alone plus ic vehicle. Astressin (1, 3 and 10 μg, ic) prevented postoperative gastric ileus by 56, 93 and 92%, respectively. Intracerebroventricular CRF (0.6 μg) and water-avoidance stress stimulated pellet output (number/60 min) to 5 ± 1 and 11 ± 2, respectively, compared with no fecal pellet output after icv vehicle and no exposure to stress. Astressin (3 and 10 μg, icv) blocked exogenous CRF action by 47 and 63%, respectively, and colonic response to stress by 0 and 54%, respectively. These data indicate that astressin injected into the CSF at low doses (1–10 μg) has an antagonistic action against CRF and stress-related alterations of gastrointestinal motor function, without an intrinsic effect in these in vivo systems. Astressin may be a useful tool to explore functional CRF-dependent physiological pathways in specific brain nuclei. The American Society for Pharmacology and Experimental Therapeutics